ZFIN Image: He et al., 2021, Fig. 4

Image

Figure Caption

Fig. 4 Sirolimus strongly inhibits proliferation in <italic>nf1/pten</italic>-mutant melanomas.

a Representative tissue sections from a transplanted nf1/pten-mutant melanoma tumor after 2 days of treatment with DMSO (CTR), 80 nM trametinib, 2 μM buparlisib, the combination of 80 nM trametinib and 2 μM buparlisib, or 20 μM sirolimus. Sections were immunostained using antibodies to detect pERK, pAKT, pS6, PCNA, and cleaved caspase-3 (CC3). pERK-, pAKT- and pS6-positive tumor areas, as well as PCNA-positive nuclei, are quantified post-treatment in (b–e). “T + B” refers to trametinib plus buparlisib. ns p > 0.05, *p < 0.05, **p < 0.01 by Mann–Whitney test. Scale bar = 20 μm.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene